Caricamento...
Azacitidine mitigates GvHD via differential effects on the proliferation of T effectors and nTregs in vivo
Azacitidine (AzaC) mitigates Graft vs. Host Disease (GvHD) in both murine preclinical transplant models and in human clinical trials while maintaining a robust Graft vs. Leukemia (GvL) effect. Previous studies have failed to investigate the role of natural Tregs on the mitigation of GvHD by AzaC; in...
Salvato in:
| Pubblicato in: | J Immunol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5541679/ https://ncbi.nlm.nih.gov/pubmed/28330901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1502399 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|